

Gian Paolo Fadini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5511140/gian-paolo-fadini-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

312
papers

12,082
citations

57
h-index

99
g-index

339
ext. papers

14,119
ext. citations

6
avg, IF

6.85
L-index

#	Paper	IF	Citations
312	Effectiveness of remote screening for diabetic retinopathy among patients referred to Mozambican Diabetes Association (AMODIA): a retrospective observational study.. <i>Acta Diabetologica</i> , 2022 , 59, 563	3.9	0
311	Response to Chia Siang Kow and colleagues.. <i>Acta Diabetologica</i> , 2022 , 59, 287	3.9	
310	Glycemic control after switching to faster aspart in adults with type 1 diabetes.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	
309	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.. <i>Nature Communications</i> , 2022 , 13, 684	17.4	0
308	Hematopoietic progenitor cell liabilities and alarmins S100A8/A9-related inflammaging associate with frailty and predict poor cardiovascular outcomes in older adults.. <i>Aging Cell</i> , 2022 , e13545	9.9	3
307	In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study.. <i>Scientific Reports</i> , 2022 , 12, 3474	4.9	0
306	Perturbation of Glucose Homeostasis During Acute Illness: Stress Hyperglycemia and Relative Hypoglycemia.. <i>Diabetes Care</i> , 2022 , 45, 769-771	14.6	1
305	Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims.. <i>Scientific Reports</i> , 2022 , 12, 7762	4.9	0
304	Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes.. <i>Computer Methods and Programs in Biomedicine</i> , 2022 , 221, 106873	6.9	1
303	105.3: Analysis of Autoimmune Re-activation After COVID-19 mRNA Vaccination in Pancreas Transplant Recipients.. <i>Transplantation</i> , 2021 , 105, S2	1.8	1
302	Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 222	8.7	0
301	Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 22-29	3.9	8
300	Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care. <i>Diabetes Research and Clinical Practice</i> , 2021 , 173, 108686	7.4	1
299	Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care. <i>European Heart Journal</i> , 2021 , 42, 2417-2419	9.5	
298	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
297	Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. <i>Cardiovascular Research</i> , 2021 ,	9.9	4
296	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. <i>Diabetes</i> , 2021 , 70, 1767-1779	0.9	4

295	Arrhythmogenic Cardiomyopathy Is a Multicellular Disease Affecting Cardiac and Bone Marrow Mesenchymal Stromal Cells. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
294	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 103	8.7	1
293	Managing diabetes in diabetic patients with COVID: where do we start from?. <i>Acta Diabetologica</i> , 2021 , 58, 1441-1450	3.9	4
292	Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targetsR attainment in subjects with and without type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 144	8.7	5
291	Assessment of simple strategies for identifying undiagnosed diabetes and prediabetes in the general population. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 75-81	5.2	1
290	Effects of glucose variability on hematopoietic stem/progenitor cells in patients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 119-126	5.2	4
289	Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3353	7.5	8
288	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 647-650	4	0
287	Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 745-753	5.2	2
286	The Toll of Lockdown Against COVID-19 on Diabetes Outpatient Care: Analysis From an Outbreak Area in Northeast Italy. <i>Diabetes Care</i> , 2021 , 44, e18-e21	14.6	10
285	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1879-1889	5.2	5
284	Recurrent Neural Network to Predict Renal Function Impairment in Diabetic Patients via Longitudinal Routine Check-up Data. <i>Lecture Notes in Computer Science</i> , 2021 , 329-337	0.9	
283	SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. <i>Cardiovascular Diabetology</i> , 2021 , 20, 39	8.7	6
282	Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies. <i>Diabetes Therapy</i> , 2021 , 12, 781-800	3.6	2
281	The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2021 , 121, 154804	12.7	2
280	Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. <i>Diabetologia</i> , 2021 , 64, 2334-2344	10.3	3
279	Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2661-2668	4.5	0
278	A Deep Learning Approach to Predict DiabetesRCardiovascular Complications From Administrative Claims. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021 , 25, 3608-3617	7.2	4

277	Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. <i>Diabetes Research and Clinical Practice</i> , 2021 , 179, 109024	7.4	1
276	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 3474-3483	4.5	3
275	Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1379-1386	5.2	15
274	Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 443-450	4.8	2
273	Why diabetes outpatient clinics should not close during pandemic crises. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1795-1798	5.2	1
272	Performance of intermittently scanned continuous glucose monitoring (isCGM) systems in people with type 1 diabetes: a pooled analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	1
271	Pharmacologic PPAR- α Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes. <i>Diabetes</i> , 2020 , 69, 1562-1572	0.9	10
270	Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss?. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 353-355	18.1	4
269	Euglycemic Ketoacidosis. <i>Current Diabetes Reports</i> , 2020 , 20, 25	5.6	11
268	Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. <i>Diabetes Therapy</i> , 2020 , 11, 1-11	3.6	105
267	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1705-1713	6.7	8
266	Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double-blind, placebo-controlled trial. <i>Stem Cells Translational Medicine</i> , 2020 , 9, 965-973	6.9	4
265	Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1946-1950	6.7	68
264	Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. <i>Cardiovascular Diabetology</i> , 2020 , 19, 74	8.7	16
263	Prevalence and impact of diabetes among people infected with SARS-CoV-2. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 867-869	5.2	247
262	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	22
261	Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. <i>Metabolism: Clinical and Experimental</i> , 2020 , 106, 154190	12.7	14
260	Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 817-827	6.7	15

259	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 161-174	3.4	55
258	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2020 , 131-159	0.1	
257	Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. <i>Acta Diabetologica</i> , 2020 , 57, 367-375	3.9	9
256	Diabetes diagnosis from administrative claims and estimation of the true prevalence of diabetes among 4.2 million individuals of the Veneto region (North East Italy). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 84-91	4.5	22
255	Circulating stem cells and cardiovascular outcomes: from basic science to the clinic. <i>European Heart Journal</i> , 2020 , 41, 4271-4282	9.5	28
254	A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe. <i>Diabetes Therapy</i> , 2020 , 11, 423-436	3.6	4
253	Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. <i>Diabetes Care</i> , 2020 , 43, 501-507	14.6	21
252	A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1945-1953	4.5	10
251	Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study. <i>Diabetes Therapy</i> , 2020 , 11, 2909-2920	3.6	
250	Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 4221-4234	3.4	6
249	Diabetes pharmacotherapy and circulating stem/progenitor cells. State of the art and evidence gaps. <i>Current Opinion in Pharmacology</i> , 2020 , 55, 151-156	5.1	3
248	Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. <i>Cardiovascular Diabetology</i> , 2020 , 19, 190	8.7	9
247	Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1925-1934	6.7	7
246	Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	9
245	Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. <i>FASEB Journal</i> , 2020 , 34, 12768-12784	0.9	7
244	Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study. <i>Diabetes Therapy</i> , 2020 , 11, 2159-2167	3.6	0
243	Performance of the Steno type 1 risk engine for cardiovascular disease prediction in Italian patients with type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1813-1819	4.5	5
242	Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19. <i>Diabetes Research and Clinical Practice</i> , 2020 , 168, 108449	7.4	4

241	Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. <i>Diabetes Research and Clinical Practice</i> , 2020 , 168, 108374	7.4	70
240	Impaired Regeneration Contributes to Poor Outcomes in Diabetic Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 34-44	9.4	19
239	Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 329-336	5.2	4
238	Diabetes mellitus impairs circulating proangiogenic granulocytes. <i>Diabetologia</i> , 2020 , 63, 1872-1884	10.3	6
237	SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes. <i>Cell Metabolism</i> , 2020 , 31, 883	24.6	4
236	Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
235	Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
234	Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5431-5444	5.6	26
233	Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study. <i>Cardiovascular Diabetology</i> , 2019 , 18, 117	8.7	8
232	Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , 2019 , 56, 1051-1060	3.9	5
231	Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. <i>Endocrine</i> , 2019 , 66, 360-369	4	7
230	Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1886-1894	6.7	12
229	Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 1099-1107	5.2	9
228	Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
227	Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. <i>Diabetes</i> , 2019 , 68, 1303-1314	0.9	33
226	Microvascular complications in diabetes: A growing concern for cardiologists. <i>International Journal of Cardiology</i> , 2019 , 291, 29-35	3.2	46
225	Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 345-349	5.2	7
224	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 252-260	6.7	25

223	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 106	8.7	16
222	Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2542-2552	6.7	13
221	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019 , 1-29	0.1	
220	Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. <i>Journal of the American Heart Association</i> , 2019 , 8, e012244	6	8
219	Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
218	Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5977-5990	5.6	8
217	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019 , 1-29	0.1	
216	Diabetic retinopathy: a tool for cardiovascular risk stratification. <i>Diabetes Mellitus</i> , 2019 , 22, 455-460	1.6	
215	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000725	4.5	19
214	Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1255-1260	6.7	8
213	Cross-talk of healthy and impaired human tissues for dissection of disease pathogenesis. <i>Biotechnology Progress</i> , 2019 , 35, e2766	2.8	
212	Loss of mitochondrial calcium uniporter rewires skeletal muscle metabolism and substrate preference. <i>Cell Death and Differentiation</i> , 2019 , 26, 362-381	12.7	28
211	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1781-1786	6.7	25
210	The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1686-1695	3.8	18
209	The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. <i>Acta Diabetologica</i> , 2018 , 55, 593-601	3.9	57
208	The continuum of monocyte phenotypes: Experimental evidence and prognostic utility in assessing cardiovascular risk. <i>Journal of Leukocyte Biology</i> , 2018 , 103, 1021	6.5	18
207	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. <i>BMJ Open Diabetes Research and Care</i> , 2018 , 6, e000475	4.5	15
206	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1367-1368	6.7	2

205	Diabetes and ischaemic stroke: a deadly association. <i>European Heart Journal</i> , 2018 , 39, 2387-2389	9.5	3
204	Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1048-1055	5.6	5
203	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. <i>Diabetes Therapy</i> , 2018 , 9, 851-861	3.6	11
202	Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 25-33	6.7	53
201	Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 740-744	6.7	25
200	Bisdemethoxycurcumin and Its Cyclized Pyrazole Analogue Differentially Disrupt Lipopolysaccharide Signalling in Human Monocyte-Derived Macrophages. <i>Mediators of Inflammation</i> , 2018 , 2018, 2868702	4.3	5
199	Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance. <i>FASEB Journal</i> , 2018 , 32, 4004-4015	0.9	8
198	Pharmacologic targeting of the diabetic stem cell mobilopathy. <i>Pharmacological Research</i> , 2018 , 135, 18-24	10.2	4
197	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2711-2723	6.7	16
196	Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying Polarization?. <i>Frontiers in Pharmacology</i> , 2018 , 9, 71	5.6	84
195	p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. <i>Cardiovascular Diabetology</i> , 2018 , 17, 16	8.7	4
194	How to interpret the role of SDF-1 α in diabetic complications during therapy with DPP-4 inhibitors. <i>Cardiovascular Diabetology</i> , 2018 , 17, 22	8.7	5
193	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018 , 1-29	0.1	
192	Circulating Stem/Progenitor Cells as Prognostic Biomarkers in Macro- and Microvascular Disease: A Narrative Review of Prospective Observational Studies. <i>Current Medicinal Chemistry</i> , 2018 , 25, 4507-4517	4.3	9
191	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018 , 131-159	0.1	
190	Diabetes mellitus as a poor mobilizer condition. <i>Blood Reviews</i> , 2018 , 32, 184-191	11.1	12
189	Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3773-3782	5.6	20
188	Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. <i>Acta Diabetologica</i> , 2018 , 55, 1121-1129	3.9	2

187	Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018 , 142, 63-73	7.4	23
186	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. <i>Diabetes Therapy</i> , 2018 , 9, 1477-1490	3.6	8
185	Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. <i>Circulation Research</i> , 2017 , 120, 1326-1340	15.7	115
184	DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 22	8.7	13
183	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1416-1424	6.7	13
182	Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2044-2050	5.6	1
181	SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. <i>Diabetologia</i> , 2017 , 60, 1385-1389	10.3	134
180	Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence. <i>Cell Metabolism</i> , 2017 , 25, 1374-1389.e6	24.6	245
179	Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. <i>Atherosclerosis</i> , 2017 , 261, 117-123	3.1	2
178	Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. <i>Atherosclerosis</i> , 2017 , 266, 95-102	3.1	29
177	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017 , 113, 1627-1638	9.9	49
176	Rationale and design of the DARWIN-T2D (Dapagliflozin Real World evldeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 1089-1097	4.5	19
175	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 680-681	18.1	97
174	PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
173	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2017 , 16, 42	8.7	49
172	Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 125-131	14.6	54
171	The rs2274911 polymorphism in GPRC6A gene is associated with insulin resistance in normal weight and obese subjects. <i>Clinical Endocrinology</i> , 2017 , 86, 185-191	3.4	23
170	Concise Review: Perspectives and Clinical Implications of Bone Marrow and Circulating Stem Cell Defects in Diabetes. <i>Stem Cells</i> , 2017 , 35, 106-116	5.8	57

169	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. <i>Cardiovascular Diabetology</i> , 2016 , 15, 111	8.7	40
168	Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. <i>Diabetes Therapy</i> , 2016 , 7, 679-693	3.6	10
167	Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 1112-1119	4.5	21
166	Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 1391-1399	5.2	66
165	Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 748-56	5.6	53
164	A perspective on NETosis in diabetes and cardiometabolic disorders. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 1-8	4.5	35
163	NETosis Delays Diabetic Wound Healing in Mice and Humans. <i>Diabetes</i> , 2016 , 65, 1061-71	0.9	155
162	Stem Cell Therapy in Diabetes 2016 , 1012-1016		
161	Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. <i>Circulation Research</i> , 2016 , 118, 1930-9	15.7	63
160	Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry. <i>Atherosclerosis</i> , 2016 , 251, 373-380	3.1	9
159	Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis. <i>Cardiovascular Therapeutics</i> , 2016 , 34, 13-20	3.3	15
158	Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 733-8	5.2	11
157	Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. <i>Vascular Pharmacology</i> , 2015 , 73, 1-3	5.9	14
156	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015 , 36, 2454-62	9.5	74
155	Diabetes modifies the relationships among carotid plaque calcification, composition and inflammation. <i>Atherosclerosis</i> , 2015 , 241, 533-8	3.1	10
154	High Temporal Resolution Detection of Patient-Specific Glucose Uptake from Human ex Vivo Adipose Tissue On-Chip. <i>Analytical Chemistry</i> , 2015 , 87, 6535-43	7.8	20
153	A perspective on sirtuins in the metabolic syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2015 , 13, 161-4	2.6	6
152	The p66(Shc) redox adaptor protein is induced by saturated fatty acids and mediates lipotoxicity-induced apoptosis in pancreatic beta cells. <i>Diabetologia</i> , 2015 , 58, 1260-71	10.3	34

151	Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF- α therapy. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 103	2.8	10
150	Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. <i>Diabetes</i> , 2015 , 64, 2957-68	0.9	66
149	Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015 , 25, 686-93	4.5	56
148	Synergistic interactions among metabolic syndrome components and homeostasis model assessment of insulin resistance in a middle-aged general population over time. <i>Metabolic Syndrome and Related Disorders</i> , 2015 , 13, 171-8	2.6	8
147	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. <i>Diabetes</i> , 2015 , 64, 2969-77	0.9	43
146	NAD(+)-dependent SIRT1 deactivation has a key role on ischemia-reperfusion-induced apoptosis. <i>Vascular Pharmacology</i> , 2015 , 70, 35-44	5.9	39
145	Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 1357-63	5.2	7
144	Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2666-72	5.6	67
143	Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. <i>Diabetes Care</i> , 2015 , 38, 1937-44	14.6	34
142	p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans. <i>Diabetologia</i> , 2015 , 58, 2352-60	10.3	22
141	Effects of Age, Diabetes, and Vascular Disease on Growth Differentiation Factor 11: First-in-Human Study. <i>Diabetes Care</i> , 2015 , 38, e118-9	14.6	11
140	NETosis is induced by high glucose and associated with type 2 diabetes. <i>Acta Diabetologica</i> , 2015 , 52, 497-503	3.9	131
139	Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 209	8.3	25
138	Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. <i>Vascular Pharmacology</i> , 2015 , 67-69, 21-9	5.9	8
137	Circulating Stem Cells Associate With Adiposity and Future Metabolic Deterioration in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4570-8	5.6	15
136	Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. <i>Diabetologia</i> , 2015 , 58, 2653-62	10.3	26
135	Alternative activation of human macrophages is rescued by estrogen treatment in vitro and impaired by menopausal status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E50-8	5.6	62
134	Phenotypic activation and pharmacological outcomes of spontaneously differentiated human monocyte-derived macrophages. <i>Immunobiology</i> , 2015 , 220, 545-54	3.4	54

133	Mechanisms of ectopic calcification: implications for diabetic vasculopathy. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 343-52	2.6	20
132	Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. <i>Diabetes</i> , 2014 , 63, 1353-65	0.9	104
131	Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. <i>Atherosclerosis</i> , 2014 , 237, 805-8	3.1	55
130	Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. <i>Stem Cells Translational Medicine</i> , 2014 , 3, 949-57	6.9	72
129	The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. <i>Diabetes Care</i> , 2014 , 37, 2884-94	14.6	122
128	Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. <i>Current Diabetes Reports</i> , 2014 , 14, 483	5.6	24
127	The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2014 , 13, 92	8.7	22
126	Age-associated cardiovascular risk and metabolomics of mitochondrial dysfunction. <i>Atherosclerosis</i> , 2014 , 232, 257-8	3.1	4
125	The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. <i>Diabetologia</i> , 2014 , 57, 1947-56	10.3	20
124	Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients. <i>Atherosclerosis</i> , 2014 , 235, 415-7	3.1	13
123	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014 , 7, 107-20	3.4	18
122	Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. <i>Current Pharmaceutical Design</i> , 2014 , 20, 2387-94	3.3	34
121	Sirtuin 1 stabilization by HuR represses TNF- α and glucose-induced E-selectin release and endothelial cell adhesiveness in vitro: relevance to human metabolic syndrome. <i>Clinical Science</i> , 2014 , 127, 449-61	6.5	27
120	Endothelial progenitor cells are reduced in acromegalic patients and can be restored by treatment with somatostatin analogs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2549-56	5.6	6
119	Ectopic calcification in diabetic vascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 595-600	3.4	11
118	A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. <i>Diabetologia</i> , 2014 , 57, 4-15	10.3	57
117	Circulating cellular players in vascular calcification. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5889-96	3.3	9
116	Restoring stem cell mobilization to promote vascular repair in diabetes. <i>Vascular Pharmacology</i> , 2013 , 58, 253-8	5.9	19

115	An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. <i>Diabetologia</i> , 2013 , 56, 1856-66	10.3	93
114	Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. <i>Acta Diabetologica</i> , 2013 , 50, 943-9	3.9	42
113	Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression. <i>Basic Research in Cardiology</i> , 2013 , 108, 368	11.8	13
112	A diseased bone marrow fuels atherosclerosis in diabetes. <i>Atherosclerosis</i> , 2013 , 226, 337-8	3.1	2
111	The endothelium abridges insulin resistance to premature aging. <i>Journal of the American Heart Association</i> , 2013 , 2, e000262	6	20
110	Monocyte-macrophage polarization balance in pre-diabetic individuals. <i>Acta Diabetologica</i> , 2013 , 50, 977-82	3.9	42
109	Diabetes impairs stem cell and proangiogenic cell mobilization in humans. <i>Diabetes Care</i> , 2013 , 36, 943-9	14.6	124
108	Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. <i>Basic Research in Cardiology</i> , 2013 , 108, 313	11.8	53
107	Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: a meta-regression analysis. <i>International Journal of Cardiology</i> , 2013 , 168, 892-7	3.2	36
106	Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. <i>Atherosclerosis</i> , 2013 , 229, 23-9	3.1	46
105	Low CD34(+) cells, high neutrophils and the metabolic syndrome are associated with an increased risk of venous thromboembolism. <i>Clinical Science</i> , 2013 , 125, 211-8	6.5	6
104	Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondin-1 overexpression. <i>FASEB Journal</i> , 2013 , 27, 4355-65	0.9	20
103	Development of metabolic syndrome and electrocardiographic features of left ventricular hypertrophy in middle-aged working subjects. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 1027-31	5.2	1
102	The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 518-22	6.7	44
101	Emerging role of circulating calcifying cells in the bone-vascular axis. <i>Circulation</i> , 2012 , 125, 2772-81	16.7	66
100	Elevated white blood cell count is associated with prevalence and development of the metabolic syndrome and its components in the general population. <i>Acta Diabetologica</i> , 2012 , 49, 445-51	3.9	28
99	Developmental cardiovascular biology meets regenerative medicine at Islet-1. <i>Atherosclerosis</i> , 2012 , 223, 282-3	3.1	
98	Increased tissue endothelial progenitor cells in end-stage lung diseases with pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 1025-30	5.8	18

97	High confidence and sensitivity four-dimensional fractionation for human plasma proteome analysis. <i>Amino Acids</i> , 2012 , 43, 2199-202	3.5	9
96	Arterio-venous gradients of endothelial progenitor cells reveal a complex kinetics in human limb ischemia. <i>Clinical Hemorheology and Microcirculation</i> , 2012 , 50, 293-300	2.5	1
95	Endothelial progenitor cells in diabetes mellitus. <i>BioFactors</i> , 2012 , 38, 194-202	6.1	63
94	The peritoneum as a natural scaffold for vascular regeneration. <i>PLoS ONE</i> , 2012 , 7, e33557	3.7	9
93	Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. <i>Circulation Research</i> , 2012 , 110, 624-37	15.7	498
92	It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. <i>Experimental Diabetes Research</i> , 2012 , 2012, 742976		35
91	Prediabetes influences cardiac rehabilitation in coronary artery disease patients. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 382-8	3.9	8
90	Strategies for enhancing progenitor cell mobilization and function in diabetes. <i>Current Vascular Pharmacology</i> , 2012 , 10, 310-21	3.3	5
89	Amelioration of glucose control mobilizes circulating pericyte progenitor cells in type 2 diabetic patients with microangiopathy. <i>Experimental Diabetes Research</i> , 2012 , 2012, 274363		12
88	Procalcific phenotypic drift of circulating progenitor cells in type 2 diabetes with coronary artery disease. <i>Experimental Diabetes Research</i> , 2012 , 2012, 921685		34
87	Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. <i>Diabetes Research and Clinical Practice</i> , 2011 , 94, 172-9	7.4	51
86	Impaired endothelial progenitor cell recruitment may contribute to heart transplant microvasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 70-6	5.8	11
85	Nutraceutical antioxidants for vascular protection? Please mind regression toward the mean. <i>Atherosclerosis</i> , 2011 , 215, 30-1	3.1	1
84	High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. <i>PLoS ONE</i> , 2011 , 6, e19603	3.7	106
83	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 718-25	6.7	42
82	Is bone marrow another target of diabetic complications?. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 457-63	4.6	21
81	At the crossroads of longevity and metabolism: the metabolic syndrome and lifespan determinant pathways. <i>Aging Cell</i> , 2011 , 10, 10-7	9.9	61
80	Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. <i>Vascular Pharmacology</i> , 2011 , 55, 10-6	5.9	166

79	Endothelial progenitor cells, bronchopulmonary dysplasia and other short-term outcomes of extremely preterm birth. <i>Early Human Development</i> , 2011 , 87, 461-5	2.2	22
78	The metabolic syndrome influences the response to incretin-based therapies. <i>Acta Diabetologica</i> , 2011 , 48, 219-25	3.9	15
77	Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. <i>Diabetologia</i> , 2011 , 54, 945-53	10.3	61
76	Microangiopathy is independently associated with presence, severity and composition of carotid atherosclerosis in type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 286-93	4.5	31
75	Endothelial dysfunction in diabetes: the role of reparatory mechanisms. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S285-90	14.6	298
74	Sarcoidosis is a Th1/Th17 multisystem disorder. <i>Thorax</i> , 2011 , 66, 144-50	7.3	162
73	Impaired hemodynamic response to meal intake in insulin-resistant subjects: an impedance cardiography approach. <i>American Journal of Clinical Nutrition</i> , 2011 , 93, 926-33	7	5
72	Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. <i>Circulation Research</i> , 2011 , 108, 1112-21	15.7	95
71	Hypoglycemic syndrome in a patient with proinsulin-only secreting pancreatic adenoma (proinsulinoma). <i>Case Reports in Medicine</i> , 2011 , 2011, 930904	0.7	11
70	Potential manipulation of endothelial progenitor cells in diabetes and its complications. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 570-83	6.7	60
69	Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. <i>Diabetes</i> , 2010 , 59, 1006-15	0.9	238
68	The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. <i>Diabetes Care</i> , 2010 , 33, 1607-9	14.6	265
67	Pharmacologic targeting of endothelial progenitor cells. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2010 , 10, 16-32	1.1	9
66	The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. <i>Diabetes</i> , 2010 , 59, 2306-14	0.9	66
65	Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. <i>European Respiratory Journal</i> , 2010 , 35, 418-25	13.6	44
64	Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 1097-102	14.6	135
63	Cell-based methods for ex vivo evaluation of human endothelial biology. <i>Cardiovascular Research</i> , 2010 , 87, 12-21	9.9	45
62	Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. <i>FASEB Journal</i> , 2010 , 24, 2262-72	0.9	30

61	Two cases of statin-induced rhabdomyolysis associated with mononeuropathy. <i>Clinical Drug Investigation</i> , 2010 , 30, 347-50	3.2	6
60	Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. <i>Cell Biology International</i> , 2010 , 34, 709-15	4.5	21
59	Reduced endothelial progenitor cells and brachial artery flow-mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary open-angle glaucoma. <i>Acta Ophthalmologica</i> , 2010 , 88, 135-41	3.7	40
58	Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. <i>Atherosclerosis</i> , 2010 , 209, 10-7	3.1	208
57	Exploring interactions among metabolic syndrome traits. Methods and meaning. <i>Atherosclerosis</i> , 2010 , 210, 45-7	3.1	2
56	A role for TGF-beta in transforming endothelial progenitor cells into neointimal smooth muscle cells. <i>Atherosclerosis</i> , 2010 , 211, 32-5	3.1	19
55	Induced pluripotent stem (iPS) cells and endothelial cell generation: SIRT-ainly a good idea!. <i>Atherosclerosis</i> , 2010 , 212, 36-9	3.1	2
54	Enhancing endothelial progenitor cell function through selective estrogen receptor modulation: a potential approach to cardiovascular risk reduction. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2010 , 8, 147-55	1.9	4
53	Insulin signaling and life span. <i>Pflugers Archiv European Journal of Physiology</i> , 2010 , 459, 301-14	4.6	45
52	Circulating smooth muscle progenitors and atherosclerosis. <i>Trends in Cardiovascular Medicine</i> , 2010 , 20, 133-40	6.9	21
51	Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome. <i>American Journal of Cardiology</i> , 2010 , 106, 1606-8	3	30
50	Improved function of circulating angiogenic cells is evident in type 1 diabetic islet-transplanted patients. <i>American Journal of Transplantation</i> , 2010 , 10, 2690-700	8.7	20
49	Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. <i>PLoS ONE</i> , 2010 , 5, e11488	3.7	72
48	Role of endothelial progenitor cells in diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 575-589	4.1	1
47	Critical confounders in the prognostic role of cellular biomarkers. <i>Kidney International</i> , 2009 , 75, 755; author reply 755-6	9.9	
46	Characteristics and mortality of type 2 diabetic patients hospitalized for severe iatrogenic hypoglycemia. <i>Diabetes Research and Clinical Practice</i> , 2009 , 84, 267-72	7.4	17
45	Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 5-10	2.6	17
44	Why to screen heart disease in diabetes. <i>Atherosclerosis</i> , 2009 , 204, 11-5	3.1	4

43	Endothelial progenitor cells as resident accessory cells for post-ischemic angiogenesis. <i>Atherosclerosis</i> , 2009 , 204, 20-2	3.1	15
42	Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. <i>Atherosclerosis</i> , 2009 , 207, 213-9	3.1	84
41	Effects of androgens on endothelial progenitor cells in vitro and in vivo. <i>Clinical Science</i> , 2009 , 117, 355-64	6.5	30
40	Low levels of endothelial progenitor cells correlate with disease duration and activity in patients with Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2009 , 27, 814-21	2.2	9
39	Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid?. <i>Free Radical Biology and Medicine</i> , 2008 , 44, 1209-15	7.8	37
38	Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. <i>Life Sciences</i> , 2008 , 82, 383-92	6.8	21
37	The metabolic syndrome, diabetes and lung dysfunction. <i>Diabetes and Metabolism</i> , 2008 , 34, 447-54	5.4	57
36	Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2008 , 82 Suppl 2, S94-S101	7.4	60
35	Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. <i>Atherosclerosis</i> , 2008 , 197, 496-503	3.1	212
34	Clones of interstitial cells from bovine aortic valve exhibit different calcifying potential when exposed to endotoxin and phosphate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 2165-72	9.4	41
33	Maternal insulin therapy increases fetal endothelial progenitor cells during diabetic pregnancy. <i>Diabetes Care</i> , 2008 , 31, 808-10	14.6	9
32	Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 997-1004	9.4	142
31	A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than-additive. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008 , 15, 190-6		22
30	An underlying principle for the study of circulating progenitor cells in diabetes and its complications. <i>Diabetologia</i> , 2008 , 51, 1091-4	10.3	30
29	Significance of endothelial progenitor cells in subjects with diabetes. <i>Diabetes Care</i> , 2007 , 30, 1305-13	14.6	137
28	Endothelial progenitor cells in coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1585; author reply 1585-6	15.1	3
27	Is the metabolic syndrome a cardiovascular risk factor beyond its specific components?. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2465; author reply 2465-6	15.1	12
26	Critical assessment of putative endothelial progenitor phenotypes. <i>Experimental Hematology</i> , 2007 , 35, 1479-80; author reply 1481-2	3.1	14

25	Glucose tolerance is negatively associated with circulating progenitor cell levels. <i>Diabetologia</i> , 2007 , 50, 2156-63	10.3	85
24	Endothelial progenitor cells and erectile dysfunction. <i>European Heart Journal</i> , 2007 , 28, 639-40; author reply 640	9.5	2
23	Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2627-33	9.4	188
22	Depletion of endothelial progenitor cells may link pulmonary fibrosis and pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 724-5; author reply 725	10.2	40
21	Endothelial progenitor cells in the natural history of atherosclerosis. <i>Atherosclerosis</i> , 2007 , 194, 46-54	3.1	153
20	The good and the bad in the link between insulin resistance and vascular calcification. <i>Atherosclerosis</i> , 2007 , 193, 241-4	3.1	36
19	The emerging role of endothelial progenitor cells in pulmonary hypertension and diffuse lung diseases. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2007 , 24, 85-93	1.1	8
18	Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. <i>Diabetologia</i> , 2006 , 49, 3075-84	10.3	227
17	Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. <i>Stroke</i> , 2006 , 37, 2277-82	6.7	182
16	Pathophysiology of circulating progenitor cells in pulmonary disease and parallels with cardiovascular disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006 , 35, 403-4	5.7	9
15	Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. <i>European Heart Journal</i> , 2006 , 27, 2247-55	9.5	197
14	Endothelial progenitor cells and the diabetic paradox. <i>Diabetes Care</i> , 2006 , 29, 714-6	14.6	73
13	Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 2140-6	9.4	352
12	Autologous transplantation of granulocyte colony-stimulating factor- mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. <i>Diabetes Care</i> , 2006 , 29, 478-9; author reply 479-80	14.6	10
11	Endothelial dysfunction in type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16 Suppl 1, S39-45	4.5	81
10	Circulating CD34+ cells, pulmonary hypertension, and myelofibrosis. <i>Blood</i> , 2006 , 108, 1776-7; author reply 1777	2.2	11
9	Circulating progenitor cells are reduced in patients with severe lung disease. <i>Stem Cells</i> , 2006 , 24, 1806-13	3.3	124
8	Arterio-venous gradient of endothelial progenitor cells across renal artery stenosis. <i>Atherosclerosis</i> , 2005 , 182, 189-91	3.1	13

7	Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1449-57	15.1	587
6	Characterization of endothelial progenitor cells. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 336, 1-2	3.4	38
5	Endothelial progenitor cells in cerebrovascular disease. <i>Stroke</i> , 2005 , 36, 1112-3; author reply 1113	6.7	12
4	Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1130-6	5.6	117
3	Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectives. <i>Current Diabetes Reviews</i> , 2005 , 1, 41-58	2.7	47
2	First isolation of <i>Burkholderia cepacia</i> from a deep neck abscess in a diabetic patient successfully treated with hyperbaric oxygen. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 529	9.7	6
1	A case of orbital myositis associated with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 383; author reply 383-4	2.4	3